US/UK/Canada

Share

Quotes

We achieved remarkable results on our eye-health ingredient in the Eurofins BioMAP in-vitro assay system employing over 140 biomarkers. The data strengthened the case for possible clinical efficacy in maintaining homeostasis of Retinal Pigment Epithelium cells (RPE cells) in the human eye. This brings us closer to the market launch of a novel and effective pre-treatment for macular degeneration to a EUR 5 billion eye-health segment utilizing Finnish circular raw materials and pharmacology competencies to drive an ophthalmologic health innovation that provides eye health protection, improves patient care outcomes, and reduces costs to the health system.
Petri Lackman, Chief Technical Officer
We were in 2022 criticized by some investors for offering too little information related to sales orders, so we lowered the threshold to KEUR 10. Lately, we have been criticized for informing about too small orders. After contemplating this, we have raised the threshold to KEUR 50 for informing about sales orders.
Stein Ulve, CEO
The BioMAP study provided unique bioactivity data on our key extracts, which strengthen our competitive position in selected nutraceutical segments.
Stein Ulve, CEO
This opportunity fits our strategy to build the business on our basic ingredients, while we develop proprietary novel prophylactic nutritional solutions addressing significant global health problems.
Erik Eide, Eevia's Commercial Director
Eevia had a transformative 2023 where we broadened our customer base and laid the foundation for strong growth in the years to come. The credit line provides for short-term working capital to continue with our strategic focus on expanding the business.
Stein Ulve, Chief Executive Officer
Although we were in contact some years ago, before Covid, we see this as the first order from this customer. Although the order is small, we are excited, because the contract manufacturer serves several large brands, and our pine bark extract has the potential to compete well. The customer is excited in general about our polyphenol products, and we expect further orders during 2024.
Anna-Maija Vanhatalo, Sales Manager at Eevia Health
It is the first order from this customer. Although the order is small, we are a bit excited, because the business came via one very well-known independent product formulator, who is kind of an “industry influencer”, and who formulates products for several large brands. We first met him in Las Vegas in October 2023, so the sales cycle was not that long. He is excited about our polyphenol products and may include our ingredients in products for other brands.
Anna-Maija Vanhatalo, Sales Manager at Eevia Health
This project is a welcome opportunity for Eevia to lock in significant revenues for 2025, and potentially for 2026 and 2027. This and similar opportunities we have in our pipeline provide traction towards achieving our long-term revenue target of EUR 25 million
Stein Ulve, Eevia's CEO
We are excited to get these orders because it is a promising start to the marketing and sale of our side stream products. It constitutes a welcome upcycling development which will impact our profitability and further our industry-leading sustainability status.
Anna-Maija Vanhatalo
The ability to offer FOB prices from New Jersey will make Eevia more competitive in the North American market. It will support our partners in North America to improve our value proposition in terms of rapid response and reliability of supply, while we reduce logistical costs.
Erik Eide
We are happy to do the “maiden shipment” under this new supply-chain arrangement. We believe keeping buffer stock in the US with ready imported materials with all certificates issued including the USDA NOP certificate for organic products, will provide better customer service and improved ability to serve smaller orders.
Anna-Maija Vanhatalo, Customer Service Manager, Eevia Health Plc
We warmly welcome Erik to this new role. His strong experience in solution sales and nutraceuticals in the international environment, has led to success in his previous roles. Erik brings a deep understanding of how companies work on operational and executive levels, and how to create value for customers. He will contribute significantly to the success and global growth of Eevia and we are extremely pleased with him joining our team.
Stein Ulve, CEO of Eevia Health Plc
The post-covid market is evolving and we are adapting. We have now significant interest in the North American market
Stein Ulve, CEO
Pick a time period -
Tags ( Active)

New sales order for 593 kSEK (51 kEUR) for a Bilberry extract

Eevia Health Plc (”Eevia” or ”The Company”) has received a sales order for 51 kEUR (593 kSEK) from a German customer for Feno-Myrtillus 36 organic, an organically certified bilberry extract.Eevia received the sales order from a German customer but with delivery to a local Finnish contract manufacturer. The product is therefore not an export revenue, but sales within Finland. Thes sales value to Eevia is c. 51 kEUR. The product is Eevia’s branded ingredient Feno-Myrtillus® 36 Organic.The customer also communicated forthcoming orders for approximately 110 kEUR for Q3-24.    For

Eevia Health Plc receives multiple sales orders for c. KSEK 1 045 (KEUR 90)

Eevia Health ("Eevia" or "The Company") received several sales orders for pine bark, bilberry, and lingonberry extracts totaling KSEK 1 045 (KEUR 90) from various European and Australian customers.The sales orders are for the following ingredient products: Fenoprolic 70 Organic (Pine bark extract) – KEUR 17, Feno-Myrtillus 25 Organic (Bilberry Extract) – KEUR 46, and Lingonberry Extract with Acacia – KEUR 27.    The orders came from several European customers with consumer brands in foods and drinks, as well as supplements. This included one order that came via our distributor in DAHC

Eevia Health Plc receives multiple sales orders for c. KSEK 518 (KEUR 50)

Eevia Health ("Eevia" or "The Company") received several sales orders totaling c 518 kSEK (50 kEUR) from various European customers.The sales orders are for the products Feno-Chaga M (Chaga extract), Feno-Myrtillus 25 Organic, Feno-Myrtillus 36 Organic (both bilberry extracts) and Fenoprolic 70 Organic (Pine bark extract). The orders came from several Finnish and European customers in the whole foods and drinks as well as supplement segments. Eevia has the product in stock, so it can deliver fast. These are repeat orders. Eevia expects further repeat orders in the future from the same

Eevia Health Plc finalizes a key development project and receives grant payment for c. 2,747 KSEK (243 KEUR)

Eevia Health ("Eevia" or "The Company") has finalized a development project for the documentation of bioactivity on its products, which was co-funded by Business Finland. Eevia executed the project in 2023 and filed the final report in February 2024. The report is now approved. Last week, Eevia received the grant payment of c. 2,747 kSEK (243 kEUR) from Business Finland.A central activity in the project was a broad in vitro screening of Eevia's top extracts on the Eurofins BioMAP phenotyping platform. The successful execution of the study provided Eevia with troves of insightful new

Eevia Health Plc receives a KSEK 1,472 (KUSD 142) sales order for Feno-Sambucus™ 7 Organic

Eevia Health ("Eevia" or "The Company") received a 1,472 kSEK / 142 kUSD blanket sales order for the elderberry extract Feno-Sambucus™ 7 Organic from a distributor in the US.The blanket order is from Select Ingredients, a distributor located in San Diego, California, US. Select Ingredients is a specialist in organic ingredients and high-quality natural plant extracts, serving branded customers in the Golden State and other large states in the US. The end customer is a company in the whole foods and drinks segment, which is experiencing fast growth across North America. The blanket

Eevia Health Plc revises its Information Policy

Eevia Health Plc (”Eevia” or ”The Company”) has revised its Information Policy and changed the threshold for orders to 566 KSEK (50 KEUR).Eevia has updated its Information Policy, according to Spotlight Stockmarket’s requirements. One out of many updates is the policy related to informing the market about sales orders and contracts. While press releases earlier were made for sales orders over 10 KEUR, such press releases will now only be made for orders or contracts with a sales value over 50 KEUR.   A press release will also be made when the accumulated value of several smaller

Eevia Health Plc Year End Report - 2023

Eevia Health Plc ("Eevia" or "The Company") is releasing its year-end financial report for the full year of 2023, as well as for Quarter 4, 2023.Summary of financial development 2023: SIGNIFICANT IMPROVEMENT IN EBITDA The EBITDA for 2023 came in positive at KEUR 753, an improvement of KEUR 1 312 from 2022 (KEUR – 559). 2023 is the first full year with positive EBITDA in the Company’s history. The improvement came from an increase of KEUR 461 in gross margin, an increase in other operating income with KEUR 127, reduced personnel cost of KEUR 378, and reduced overhead of KEUR 349.

Eevia Health Plc engages with a global market leader to evaluate collaboration on the launch of a novel dietary eye-health ingredient

Eevia Health Plc (”Eevia” or ”The Company”) is exchanging confidential information with a global market leader in eye health regarding a novel ingredient Eevia developed over the last 4 years.The counterpart is a global market leader in eye health products with EUR 4.5 billion annual turnover and a global market reach. The purpose is to evaluate collaboration on a market launch for an oral prophylactic for healthy people ‘at risk’ of developing AMD[1]. The parties will also consider an application to slow the progression for people already diagnosed with AMD.   According to WHO[2], 1.

Eevia Health Plc has secured a credit line of SEK 7.2 million for working capital purposes to finance continued growth

Eevia Health Plc, (”Eevia” or ”The Company”), has entered into an agreement whereby Råsunda Förvaltning AB, Upgrade Invest Nordic AB, and Renewable Ventures Nordic AB will provide a credit line for Eevia of up to SEK 7.2 million (EUR 640,000) giving the Company increased working capital flexibility to finance its continued growth. The term of the Credit line is until June 30, 2024, and it is unsecured. Interest is charged at two (2.0) percent per month and a five (5) percent arrangement fee.Stein Ulve, Chief Executive Officer states: “Eevia had a transformative 2023 where we broadened our

Eevia Health Plc received a 445 KSEK / 39 KEUR sales order for a Bilberry extract

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 39 KEUR sales order from a French distributor Natural Ingredients, for Feno-Myrtillus 25, a bilberry extract.The sales value to Eevia of this new order is kEUR 39. The product is Feno-Myrtillus® 25, which is a highly concentrated bilberry extract with 25% anthocyanins.  The customer is Natural Ingredients, a French distributor company located near Angers, in the Loire Valley. Their specialty is natural and functional ingredients for the food supplement industry.  Natural Ingredients' reputation for delivering high-quality

Eevia Health Plc received a 159 KSEK / 14 KEUR sales order for a pine bark extract product

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 14 KEUR sales order from a US company for Fenoprolic®  70 Organic, an organically certified pine bark extract.The customer is a medium-sized US contract manufacturer that manufactures consumer-ready dosage forms, such as tablets, lozenges, hard-gel capsules, and similar, for various brand holders across North America. The contract manufacturer also has its own brand. The end customer is a well-known brand that has a very strong position within organic and natural supplements in the US.   The sales value to Eevia of this new

Eevia Health Plc received a 112 KSEK / 10 KEUR sales order for a Bilberry extract product

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 10 KEUR sales order from a US company for Feno-Myrtillus 25 organic, an organically certified bilberry extract.The customer is a medium-sized US brand holder with distribution throughout North America. The sales value to Eevia of this new order is kEUR 10 and the product is in stock. The product is Eevia’s branded ingredient Feno-Myrtillus® 25 Organic, which is a highly concentrated and organically certified bilberry extract with 25% anthocyanins. “It is the first order from this customer. Although the order is small, we are a

Eevia Health Plc receives a 289 KSEK / 25 KEUR sales order for a Lingonberry extract product

Eevia Health Plc (”Eevia” or ”The Company”) has received a 25 KEUR sales order for a Lingonberry extract from a Finnish beauty brand.The end customer is a leading Finnish manufacturer and brand owner of cosmetics, who markets and sells high-end cosmetic products in Europe, Asia, and North America. The company is known for its relentless focus on sustainable development practices and natural arctic product lines. The sales value of this order is c. 25 kEUR, and the product is a lingonberry extract standardized on key polyphenols made with a custom-made specialized production protocol and

Eevia Health Plc enters negotiations for a significant sales contract for 2025 with an option to extend until 2027

Eevia Health Plc (”Eevia” or the “Company”) has entered negotiations with a European food manufacturer to manufacture a new plant extract (the “Product”) with the potential for significant contribution to the Company’s topline and profits in 2025. The manufacturing would start earliest in December 2024 and will require 20% to 40% of Eevia's annual production capacity for 2025, with an option to extend both annual volumes and the contract period till 2027. The parties expect to finalize negotiations by the end of Q1-2024.The customer is a listed and well-established medium-sized European

Eevia Health Plc received two sales orders totaling 516 kSEK / 46 kEUR for Bilberry juice powder made from side streams of Eevia’s main berry extract production

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 46 kEUR (516 kSEK) sales order from a Finnish customer for organically certified Bilberry Juice powder.Eevia received a new order from a Finnish customer for a bilberry juice powder product. The product is Bilberry Juice Powder Organic, which is an unstandardized organically certified bilberry juice powder. The product is made from side streams of Eevia’s extract production. It is one of the first major orders for this product. Eevia has the product in stock. The Finnish customer is a local contract manufacturer that serves

Eevia Health Plc reorganizes distribution in North America

Eevia Health Plc’s (”Eevia” or ”The Company”) has reorganized distribution in North America with an objective to have a more transparent the value chain beyond the distributors, with shorter lead times to end clients and reduced logistic costs.Eevia decided early 2023 on a new policy to always know the end client of the sales in all territories. This requires transparency with our distributors. We are therefore critically evaluating distributors that do not reveal who the end customer is and prioritizing the collaboration with distributors which works on an open basis. In entering new

Eevia Health Plc received an increase of 115 kSEK / 11 kEUR to an earlier sales order for a Bilberry extract worth 228 SEK / 21 kEUR

Eevia Health Plc’s (”Eevia” or ”The Company”) has received an extension of 11 kEUR (115 kSEK) to the sales order of 22 kEUR (228 kSEK) which was press released by Eevia on December 20th 2023. The order and extra-order is from a German customer for Feno-Myrtillus 36 organic, an organically certified bilberry extract.Eevia received an increase to a sales order a German customer made on December 20th, 2023. The sales value to Eevia of this additional order is c. kEUR 11 EUR, so the total sales order is now kEUR 33. Eevia has the product in stock for immediate delivery. The product is Eevia’s

Eevia Health Plc received a multiple sales order for extract products with combined value of 347 KSEK / 31 KEUR

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a series of smaller orders worth a total of 31 KEUR sales order from Slovenian and Taiwanese customers for organically certified bilberry and chaga extracts.The customers are existing customers located in Slovenia and Taiwan, who order regularly. The products are Eevia’s branded ingredient Feno-Myrtillus® 25 Organic, Feno-Myrtillus® 5 Organic, Fenoprolic® Full Spectrum (a pine bark extract) and a Chaga powder. The sales value to Eevia of the new orders is kEUR 31 and the products ordered are in stock. The order is expected to be

Eevia Health Plc receiveS A 763 Ksek (69 KEUR) sales order for Feno-Sambucus™ 7 Organic

Eevia Health ("Eevia" or "The Company") received a 763 kSEK / 69 kEUR sales order for the elderberry extract Feno-Sambucus™ 7 ORGANIC from a distributor in the US.The order is from Select Ingredients, a distributor located in San Diego, California, US. Select Ingredients is a specialist in organic ingredients and high-quality natural plant extracts, serving branded customers in the Golden State and other large states in the US. The order end customer is a company in the whole foods and drinks segment, which is experiencing very fast growth across North America. This order is the first

Eevia Health Plc received a 434 KSEK / 39 KEUR sales order for a Bilberry extract product

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 39 KEUR sales order from French distributor Natural Ingredients, for Feno-Myrtillus 25 organic, an organically certified bilberry extract.Natural Ingredients is a French distributor company located near Angers, in the Loire Valley. Their specialty is natural and functional ingredients for the food supplement industry.  Natural Ingredients' reputation for delivering high-quality natural products aligns perfectly with Eevia Health's mission to promote health and well-being using sustainable arctic botanical extracts. The sales

Eevia Health Plc received a 228 kSEK / 21 kEUR sales order for a Bilberry extract product

Eevia Health Plc’s (”Eevia” or ”The Company”) has received a 21 kEUR (228 kSEK) repeat sales order from a German customer for Feno-Myrtillus 36 organic, an organically certified bilberry extract.Eevia received a new repeat order from a German customer for a bilberry extract. The German customer develops and markets vegan vitamins, superfoods, and sports nutrition under well-known brands. They use high quality raw materials in their own, innovative recipes.  The company maintains strict quality control and exclusively vegan products. The sales value to Eevia of this new order is c. kEUR

Eevia Health Plc appoints Erik Eide as Commercial Director

Eevia Health Plc, ("Eevia" or "The Company") is welcoming Erik Eide in the new position as Commercial Director starting December 19. Based in Victoria, British Columbia, Canada, he will lead Eevia’s global marketing and sales efforts.To advance the commercial development of the company, Eevia Health is excited to announce that Erik Eide has joined the organization as Commercial Director. It is a new position that will be key to future revenue generation. Erik’s focus is on developing Eevia Health's position as a trusted supplier of nutraceutical ingredients. He complements the leadership

Eevia Health Plc receives a 520 kSEK (47 kEUR) sales order for a Bilberry extract

Eevia Health Plc, (”Eevia” or ”The Company”), has received a 47 kEUR sales order from a European nutraceutical brand owner with delivery in December 2023.The customer is a European brand owner headquartered in Sweden. The customer develops and markets effective herbal dietary supplements, as well as cosmetics in over 50.000 pharmacies, health food shops, and other retail outlets across 36 countries, including China and USA. The purchase order is a repeat order with a sales value to Eevia of c. 47 kEUR for delivery in December. Eevia has the product in stock. The product is Feno-

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media